FAQ

hepatitis E vaccine

Known as: Hep E 
 

Topic mentions per year

Topic mentions per year

2000-2018
0246820002018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Modeling the long-term antibody response of a hepatitis E vaccine.
BACKGROUND The first commercialized hepatitis E vaccine, HEV 239, has been shown to be safe and highly immunogenic, the… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults.
A recombinant hepatitis E vaccine, Hecolin, has been proven safe and effective in healthy adults. As hepatitis B surface antigen… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial.
BACKGROUND Seroprevalence data suggest that a third of the world's population has been infected with the hepatitis E virus. Our… (More)
Is this relevant?
2009
2009
Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine.
The candidate recombinant hepatitis E vaccine, HEV 239, protect monkeys against infection by hepatitis E virus (HEV). The safety… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Safety and efficacy of a recombinant hepatitis E vaccine.
BACKGROUND Hepatitis E virus (HEV) is an important cause of viral hepatitis. We evaluated the safety and efficacy of an HEV… (More)
Is this relevant?
2007
2007
The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E.
To test the possibility of developing a combined vaccine against hepatitis A and E, groups of mice were immunized with different… (More)
Is this relevant?
2005
2005
A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.
It was evaluated its antigenicity, immunogenicity and efficacy of a candidate recombinant hepatitis E virus (HEV) vaccine… (More)
Is this relevant?
2005
2005
A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus.
A candidate hepatitis E vaccine is composed of amino acids (aa) 112-607 of the 660-aa protein encoded by open reading frame 2… (More)
Is this relevant?
2004
2004
Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles.
Hepatitis E virus (HEV) is an important causative agent of enterically-transmitted hepatitis. Successful vaccine development is… (More)
Is this relevant?
2003
2003
Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine.
We have demonstrated that recombinant hepatitis E vaccine suitable for clinical evaluation was highly immunogenic and efficacious… (More)
Is this relevant?